Brief: Cytokinetics Announces FDA Approval Of Myqorzo™ (Aficamten)

Cytokinetics, Incorporated

19/12/2025 21:11

Dec 19 (Reuters) - Cytokinetics Inc CYTK.O:

CYTOKINETICS INC - MYQORZO EXPECTED TO BE AVAILABLE IN U.S. JANUARY 2026

CYTOKINETICS INC - MYQORZO INCLUDES BOXED WARNING FOR RISK OF HEART FAILURE

CYTOKINETICS ANNOUNCES FDA APPROVAL OF MYQORZO™ (AFICAMTEN) FOR THE TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS

CYTOKINETICS INC - MYQORZO AVAILABLE ONLY THROUGH RESTRICTED REMS PROGRAM

Source text: ID:nGNX4L2G4W

Further company coverage: CYTK.O

 ((Reuters.Briefs@thomsonreuters.com;))